Oncocyte (NASDAQ:IMDX – Get Free Report) and Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.
Volatility and Risk
Oncocyte has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
Profitability
This table compares Oncocyte and Werewolf Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncocyte | -2,955.63% | N/A | -107.52% |
| Werewolf Therapeutics | N/A | -166.99% | -59.88% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncocyte | 1 | 0 | 2 | 0 | 2.33 |
| Werewolf Therapeutics | 1 | 3 | 2 | 1 | 2.43 |
Oncocyte presently has a consensus target price of $10.50, indicating a potential upside of 254.73%. Werewolf Therapeutics has a consensus target price of $4.00, indicating a potential upside of 305.64%. Given Werewolf Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Oncocyte.
Insider & Institutional Ownership
55.3% of Oncocyte shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 2.2% of Oncocyte shares are owned by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Oncocyte and Werewolf Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncocyte | $1.67 million | 58.00 | -$50.22 million | ($1.49) | -1.99 |
| Werewolf Therapeutics | $21.00 million | 2.28 | -$60.82 million | ($0.76) | -1.30 |
Oncocyte has higher earnings, but lower revenue than Werewolf Therapeutics. Oncocyte is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Werewolf Therapeutics beats Oncocyte on 10 of the 14 factors compared between the two stocks.
About Oncocyte
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
